151 related articles for article (PubMed ID: 24749658)
21. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?
Dick J; Enk A; Hassel JC
Dermatology; 2015; 230(1):8-10. PubMed ID: 25531526
[TBL] [Abstract][Full Text] [Related]
22. Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma.
Ohtsuka M; Miura T; Mori T; Ishikawa M; Yamamoto T
JAMA Dermatol; 2015 Jul; 151(7):797-9. PubMed ID: 25875052
[No Abstract] [Full Text] [Related]
23. Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis.
Beniwal-Patel P; Matkowskyj K; Caldera F
J Gastrointestin Liver Dis; 2015 Sep; 24(3):274. PubMed ID: 26405697
[No Abstract] [Full Text] [Related]
24. Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS; Kähler KC; Hauschild A
J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
[TBL] [Abstract][Full Text] [Related]
25. Polymyalgia rheumatica occurring during treatment with ipilimumab.
Maniu C; Kobe C; Schlaak M; Mauch C; Eming SA
Eur J Dermatol; 2016 Oct; 26(5):513-514. PubMed ID: 27349150
[No Abstract] [Full Text] [Related]
26. Ipilimumab-induced hypophysitis: early Australian experience.
De Sousa SM; Long GV; Tonks KT
Med J Aust; 2014 Aug; 201(4):198-9. PubMed ID: 25164840
[No Abstract] [Full Text] [Related]
27. Vemurafenib-induced panniculitis.
Villani AP; Zaharia D; Dalle S; Depaepe L; Balme B; Thomas L
Eur J Dermatol; 2013 Apr; 23(2):258-60. PubMed ID: 23567624
[No Abstract] [Full Text] [Related]
28. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
Mochel MC; Ming ME; Imadojemu S; Gangadhar TC; Schuchter LM; Elenitsas R; Payne AS; Chu EY
J Cutan Pathol; 2016 Sep; 43(9):787-91. PubMed ID: 27161449
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
[TBL] [Abstract][Full Text] [Related]
30. [Ipilimumab-induced hypophysitis].
Schleder S; Schreml S; Heiss P
Rofo; 2013 Mar; 185(3):268-9. PubMed ID: 23154861
[No Abstract] [Full Text] [Related]
31. Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio.
Indini A; Di Nicola M; Del Vecchio M; De Braud F
J Clin Oncol; 2016 Mar; 34(9):1017-8. PubMed ID: 26786928
[No Abstract] [Full Text] [Related]
32. Ipilimumab (Yervoy) and inoperable or metastatic melanoma. More evaluation needed, in both first- and second-line use.
Prescrire Int; 2015 Apr; 24(159):96. PubMed ID: 25941700
[No Abstract] [Full Text] [Related]
33. Ponatinib-induced widespread ichthyosiform eruption.
Derlino F; Barruscotti S; Zappasodi P; Brazzelli V; Vassallo C
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e519-e521. PubMed ID: 28557248
[No Abstract] [Full Text] [Related]
34. Interleukin-2-associated bullous drug dermatosis.
Hofmann M; Audring H; Sterry W; Trefzer U
Dermatology; 2005; 210(1):74-5. PubMed ID: 15604553
[No Abstract] [Full Text] [Related]
35. A Case of Perforating Folliculitis Induced by Vemurafenib.
Shiraishi K; Masunaga T; Tohyama M; Sayama K
Acta Derm Venereol; 2019 Feb; 99(2):230-231. PubMed ID: 30281138
[No Abstract] [Full Text] [Related]
36. Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
Zonta E; Chiarion V; Zarian H; Peserico A; Alaibac M
Melanoma Res; 2012 Jun; 22(3):284-5. PubMed ID: 22543678
[No Abstract] [Full Text] [Related]
37. [A new form of hypophisitis following ipilimumab therapy].
Schmutz JL
Ann Dermatol Venereol; 2015 Apr; 142(4):307-8. PubMed ID: 25770731
[No Abstract] [Full Text] [Related]
38. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
[No Abstract] [Full Text] [Related]
39. Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab - case report.
Dilling P; Walczak J; Pikiel P; Kruszewski WJ
Pol Przegl Chir; 2014 Feb; 86(2):94-6. PubMed ID: 24670341
[TBL] [Abstract][Full Text] [Related]
40. Rosaceiform eruption induced by cetuximab.
Fernández-Torres R; Martínez Gomez W; Cuevas Santos J; Paradela S; Fonseca Capdevila E
Eur J Dermatol; 2010; 20(3):392-3. PubMed ID: 20172848
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]